The "pROCAINA (PROstate CAncer INdication Attitudes) Project" (Part II) - A survey among Italian radiation oncologists on radical radiotherapy in prostate cancer;Il progetto PROCAINA (PROstate CAncer INdication Attitudes) (Parte II) - Una survey tra gli oncologi radioterapisti italiani sulla radioterapia radicale per il tumore prostatico

Radiologia Medica

Volumn 118, Issue 7, 2013, Pages 1220-1239

  De Bari, Berardino ^a   Alongi, Filippo ^b   Franco, Pierfrancesco ^c   Ciammella, Patrizia ^d   Chekrine, Tarik ^e   Livi, Lorenzo ^f   Jereczek Fossa, Barbara A ^g   Filippi, Andrea Riccardo ^h  

^a SPEDALI CIVILI   (Italy)

^b HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^c Ospedale Regionale U Parini   (Italy)

^d S MARIA NUOVA HOSPITAL   (Italy)

^e IBN ROCHD UNIVERSITY HOSPITAL   (Morocco)

^f UNIVERSITY OF FLORENCE   (Italy)

^g UNIVERSITY OF MILAN   (Italy)

^h UNIVERSITY OF TURIN   (Italy)

Author keywords

Hormonal therapy; PROCAINA; Prostate cancer; Radical radiotherapy; Survey

Indexed keywords

ARTICLE; CANCER GRADING; CANCER STAGING; CLINICAL PRACTICE; HUMAN; ITALY; MALE; MULTICENTER STUDY; PATHOLOGY; PROSTATE TUMOR; STATISTICS; CLINICAL TRIAL; PROSTATIC NEOPLASMS; STATISTICS AND NUMERICAL DATA;

HUMANS; ITALY; MALE; NEOPLASM GRADING; NEOPLASM STAGING; PHYSICIAN'S PRACTICE PATTERNS; PROSTATIC NEOPLASMS;

EID: 84888012608     PISSN: 00338362     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11547-013-0925-z     Document Type: Article

References (62)

1. Jemal A, Bray F, Center MM et al (2011) Global cancer statistics. CA Cancer J Clin 61: 69-90. Epub 2011 Feb 4. Erratum in: CA Cancer J Clin 61:134
2. Kuban DA, Thames HD, Levy LB et al (2003) Long-term multi-institutional analysis of stage T1-T2 prostate cancer treated with radiotherapy in the PSA era. Int J Radiat Oncol Biol Phys 57:915-928
3. Shipley WU, Thames HD, Sandler HM et al (1999) Radiation therapy for clinically localized prostate cancer: a multi-institutional pooled analysis. JAMA 281:1598-1604
4. Vieillot S, Fenoglietto P, Aillères N et al (2010) Prostate cancer. Cancer Radiother 14:S161-S173
5. Teoh M, Clark CH, Wood K et al (2011) Volumetric modulated arc therapy: a review of current literature and clinical use in practice. Br J Radiol 84:967-996
6. Sale C, Moloney P (2011) Dose comparisons for conformal, IMRT and VMAT prostate plans. J Med Imaging Radiat Oncol 55:611-621
7. Sze HC, Lee MC, Hung WM et al (2012) RapidArc radiotherapy planning for prostate cancer: Single-arc and double-arc techniques vs. intensitymodulated radiotherapy. Med Dosim 37:87-89
8. Yeung TP, Yartsev S, Rodrigues G, Bauman G (2011) Evaluation of image-guidance strategies with helical tomotherapy for localised prostate cancer. J Med Imaging Radiat Oncol 55:220-228
9. Magrini SM, Bertoni F, Vavassori V et al (2002) Practice patterns for prostate cancer in nine central and northern Italy radiation oncology centers: a survey including 1759 patients treated during two decades (1980-1998). Int J Radiat Oncol Biol Phys 52:1310-1319
10. Padhani AR (2011) Integrating multiparametric prostate MRI into clinical practice. Cancer Imaging 11:S27-S37
11. Clyne M (2011) Prostate cancer: PETCT for pelvic node staging. Nat Rev Urol 8:649
12. Bauman G, Belhocine T, Kovacs M et al (2012) (18)F-fluorocholine for prostate cancer imaging: a systematic review of the literature. Prostate Cancer Prostatic Dis 15:45-55
13. Alongi F, De Bari B, Franco F et al on behalf of AIRO Young and AIRO Prostate cancer Working Group (2013) The "PROCAINA (PROstate CAncer INdication Attitudes) Project" (Part I) - A survey among Italian radiation oncologists on post-operative radiotherapy in prostate cancer. Radiol Med, 2013 Jan 28 [Epub ahead of print]
14. D'Amico AV, Moran BJ, Braccioforte MH et al (2009) Risk of death from prostate cancer after brachytherapy alone or with radiation, androgen suppression therapy, or both in men with high-risk disease. J Clin Oncol 27:3923-3928
15. Heidenreich A, Bellmunt J, Bolla M et al (2011) EAU Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Treatment of Clinically Localised Disease. Eur Urol 59:61-71
16. Sullivan R, Peppercorn J, Sikora K et al (2011) Delivering affordable cancer care in high-income countries. Lancet Oncol 15:933-980
17. Valdagni R, Albers P, Bangma C et al (2011) The requirements of a specialist Prostate Cancer Unit: a discussion paper from the European School of Oncology. Eur J Cancer 47:1-7
18. Miller DC, Gruber SB, Hollenbeck BK, Montie JE, Wei JT (2006) Incidence of initial local therapy among men with lower-risk prostate cancer in the United States. Natl Cancer Inst 98(16):1134-1141
19. Chodak GW, Thisted RA, Gerber GS et al (1994) Results of conservative management of clinically localized prostate cancer. N Engl J Med 330:242-248
20. Albertsen PC, Hanley JA, Fine J (2005) 20-year outcomes following conservative management of clinically localized prostate cancer. JAMA 293:2095-2101
21. Albertsen PC, Hanley JA, Gleason DF, Barry MJ (1998) Competing risk analysis of men aged 55 to 74 years at diagnosis managed conservatively for clinically localized prostate cancer. JAMA 280:975-980
22. Klotz L, Zhang L, Lam A et al (2010) Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer. J Clin Oncol 28:126-131
23. Tan CH, Wang J, Kundra V (2011) Diffusion weighted imaging in prostate cancer. Eur Radiol 21:593-603
24. Alonzi R, Padhani AR, Allen C (2007) Dynamic contrast enhanced MRI in prostate cancer. Eur J Radiol 63:335-350
25. Verma S, Rajesh A, Fütterer JJ et al (2010) Prostate MRI and 3D MR spectroscopy: how we do it. AJR Am J Roentgenol 194:1414-1426
26. Hara T, Kosaka N, Kishi H (1998) PET imaging of prostate cancer using carbon-11-choline. J Nucl Med 39:990-995
27. Farsad M, Schiavina R, Castellucci P et al (2005) Detection and localization of prostate cancer: correlation of (11) C-choline PET/CT with histopathologic step-section analysis. J Nucl Med 46:1642-1649
28. 11C-choline positron emission tomography/computerized tomography for tumor localization of primary prostate cancer in comparison with 12-core biopsy. J Urol 176:954-960; discussion 960. Erratum in J Urol 176:2749
29. Husarik DB, Miralbell R, Dubs M et al (2008) Evaluation of [(18)F]-choline PET/CT for staging and restaging of prostate cancer. Eur J Nucl Med Mol Imaging 35:253-263
30. Kotzerke J, Prang J, Neumaier B et al (2000) Experience with carbon-11 choline positron emission tomography in prostate carcinoma. Eur J Nucl Med 27:1415-1419
31. Reske SN, Blumstein NM, Neumaier B et al (2006) Imaging prostate cancer with 11C-choline PET/CT. J Nucl Med 47:1249-1254
32. Kwee SA, Coel MN, Lim J, Ko JP (2005) Prostate cancer localization with 18 fluorine fluorocholine positron emission tomography. J Urol 173:252-255
33. Li X, Liu Q, Wang M et al (2008) C-11 Choline PET/CT imaging for differentiating malignant from benign prostate lesions. Clin Nucl Med 33:671-676
34. Skanjeti A, Pelosi E (2011) Lymph node staging with choline PET/CT in patients with prostate cancer: a review. ISRN Oncol 219064
35. Hennequin C, Rivera S, Quero L, Latorzeff I (2010) Prostate cancer: doses and volumes of radiotherapy. Cancer Radiother 14:474-478
36. Engelbrecht MR, Jager GJ, Laheij RJ et al (2002) Local staging of prostate cancer using magnetic resonance imaging: a meta-analysis. Eur Radiol 12:294-2302
37. Kestin L, Goldstein N, Vicini F et al (2002) Treatment of prostate cancer with radiotherapy: should the entire seminal vesicles be included in the clinical target volume? Int J Radiat Oncol Biol Phys 54:686-697
38. Mutanga TF, de Boer HC, van der Wielen GJ et al (2011) Margin evaluation in the presence of deformation, rotation, and translation in prostate and entire seminal vesicle irradiation with daily marker-based setup corrections. Int J Radiat Oncol Biol Phys 81:1160-1167
39. Meijer GJ, de Klerk J, Bzdusek K et al (2008) What CTV-to-PTV margins should be applied for prostate irradiation? Four-dimensional quantitative assessment using modelbased deformable image registration techniques. Int J Radiat Oncol Biol Phys 72:1416-1425
40. Seaward SA, Weinberg V, Lewis P et al (1998) Identification of a high-risk clinically localized prostate cancer subgroup receiving maximum benefit from whole-pelvic irradiation. Cancer J Sci Am 4:370-377
41. Ploysongsang SS, Aron BS, Shehata WM (1992) Radiation therapy in prostate cancer: whole pelvis with prostate boost or small field to prostate? Urology 40:18-26
42. Seaward SA, Weinberg V, Lewis P et al (1998) Improved freedom from PSA failure with whole pelvic irradiation for high-risk prostate cancer. Int J Radiat Oncol Biol Phys 42:1055-1062
43. Roach M III, Marquez C, Yuo HS et al (1994) Predicting the risk of lymph node involvement using the pretreatment prostate specific antigen and Gleason score in men with clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 28:33-37
44. Asbell SO, Martz KL, Shin KH et al (1998) Impact of surgical staging in evaluating the radiotherapeutic outcome in RTOG #77-06, a phase III study for T1BN0M0 (A2) and T2N0M0 (B) prostate carcinoma. Int J Radiat Oncol Biol Phys 40:769-782
45. Lawton CA, DeSilvio M, Roach M III et al (2007) An update of the phase III trial comparing whole pelvic to prostate only radiotherapy and neoadjuvant to adjuvant total androgen suppression: updated analysis of RTOG 94-13, with emphasis on unexpected hormone/ radiation interactions. Int J Radiat Oncol Biol Phys 69:646-655
46. Pommier P, Chabaud S, Lagrange JL et al (2007) Is there a role for pelvic irradiation in localized prostate adenocarcinoma? Preliminary results of GETUG-01. J Clin Oncol 25:5366-5373
47. www.nccn.org, NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines 4.2011 (Last access on 10 May 2013)
48. Pollack A, Zagars GK, Starkschall G et al (2002) Prostate cancer radiation dose response: results of the M. D. Anderson phase III randomized trial. Int J Radiat Oncol Biol Phys 53:1097-1105
49. Peeters ST, Heemsbergen WD, Koper PC et al (2006) Dose-response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy. J Clin Oncol 24:1990-1996
50. Latorzeff I, Mazurier J, Boutry C et al (2010) Benefit of intensity modulated and image-guided radiotherapy in prostate cancer. Cancer Radiother 14:479-487
51. Kuban DA, Tucker SL, Dong L et al (2008) Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer. Int J Radiat Oncol Biol Phys 70:67-74
52. Beckendorf V, Guerif S, Le Prisé E et al (2011) 70 Gy versus 80 Gy in localized prostate cancer: 5-year results of GETUG 06 randomized trial. Int J Radiat Oncol Biol Phys 80:1056-1063
53. Brenner DJ, Martinez AA, Edmundson GK (2002) Direct evidence that prostate tumors show high sensitivity to fractionation (low alpha/beta ratio), similar to late-responding normal tissue. Int J Radiat Oncol Biol Phys 52:6-13
54. Wang JZ, Guerrero M, Li XA (2003) How low is the alpha/beta ratio for prostate cancer? Int J Radiat Oncol Biol Phys 55:194-203
55. Ko EC, Forsythe K, Buckstein M et al (2011) Radiobiological rationale and clinical implications of hypofractionated radiation therapy. Cancer Radiother 15:221-229
56. Azria D, Aillères N, Llacer Moscardo C et al (2009) Radiothérapie de conformation avec modulation d'intensité dans le cancer de prostate: vers un nouveau standard. Cancer Radiother 13:409-415
57. de Crevoisier R, Garcia R, Louvel G et al (2009) Cone beam CT based image guided radiotherapy: implementation and clinical use. Cancer Radiother 13:482-489
58. Lisbona A, Averbeck D, Supiot S et al (2010) IMRT combined to IGRT: increase of the irradiated volume. Consequences? Cancer Radiother 14:563-570
59. Gelblum DY, Potters L, Ashley R et al (1999) Urinary morbidity following ultrasound-guided transperineal prostate seed implantation. Int J Radiat Oncol Biol Phys 45:59-67
60. Alemozaffar M, Regan MM, Cooperberg MR et al (2011) Prediction of erectile function following treatment for prostate cancer. JAMA 306:1205-1214
61. Zelefsky MJ, Kuban DA, Levy LB et al (2007) Multi-institutional analysis of long-term outcome for stages T1-T2 prostate cancer treated with permanent seed implantation. Int J Radiat Oncol Biol Phys 67:327-333
62. Yamada Y, Rogers L, Demanes DJ et al (2012) American Brachytherapy Society consensus guidelines for high-dose-rate prostate brachytherapy. Brachytherapy 11:20-32